Short Interest in Oncolytics Biotech Inc. (NASDAQ:ONCY) Grows By 35.0%

Oncolytics Biotech Inc. (NASDAQ:ONCY) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 3,550,000 shares, an increase of 35.0% from the January 15th total of 2,630,000 shares. Based on an average daily trading volume, of 1,170,000 shares, the short-interest ratio is currently 3.0 days.

Institutional Investors Weigh In On Oncolytics Biotech

A number of hedge funds have recently bought and sold shares of ONCY. International Assets Investment Management LLC lifted its stake in shares of Oncolytics Biotech by 15.0% in the fourth quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock valued at $186,000 after buying an additional 26,069 shares during the period. Vantage Point Financial LLC acquired a new position in Oncolytics Biotech in the fourth quarter worth about $27,000. Virtu Financial LLC acquired a new stake in shares of Oncolytics Biotech during the fourth quarter worth approximately $90,000. National Bank of Canada FI increased its holdings in shares of Oncolytics Biotech by 199.6% during the fourth quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock worth $60,000 after buying an additional 42,955 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Oncolytics Biotech by 59.6% during the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock worth $61,000 after buying an additional 24,997 shares in the last quarter. 6.82% of the stock is currently owned by institutional investors.

Oncolytics Biotech Stock Down 0.6 %

ONCY stock traded down $0.00 during mid-day trading on Friday, reaching $0.77. 263,905 shares of the stock traded hands, compared to its average volume of 2,672,717. Oncolytics Biotech has a 52 week low of $0.67 and a 52 week high of $1.53. The business has a 50-day moving average of $0.83 and a two-hundred day moving average of $0.96. The firm has a market capitalization of $61.39 million, a PE ratio of -2.84 and a beta of 1.24.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Oncolytics Biotech in a research report on Monday, February 3rd. Leede Financial downgraded shares of Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research note on Wednesday, November 13th. Finally, Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.